Will J&J TRANSFORM Esketamine Into A Viable Depression Treatment?

 
• By Daniel Chancellor
  
Sad boy
Approval of J&J's esketamine could give the wider depression market a new direction for growth • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category